ArticleTechnical innovations & patient support in radiation oncology2026
Dosimetric impact of daily skin surface variations in kidney stereotactic ablative proton therapy.
Article in Technical innovations & patient support in radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Proton beam therapy (PBT) is a promising modality in kidney stereotactic ablative radiotherapy (SABR). However, the sensitivity of PBT to materials in the beam path enforces special considerations in patient positioning. In clinical practice, we observed significant variability in the skin surface, which may perturb delivered dose. Here, we characterize the impact of skin surface variations in kidney stereotactic body proton therapy (SBPT). Materials and methods: Patients treated with kidney SBPT between 2024 and 2025 were included. Assessment plans were created using 3.0 mm positioning uncertainty in robust optimization to deliver a prescription dose of 50 Gy(RBE) in 5 fractions to 99% of the target volume (iCTV). Virtual CTs were generated for dose accumulation by mapping HU from the planning scan onto the day-of-treatment CBCT. The assessment plan was mapped to each virtual CT set. The dose to 95-100% of the target (iCTV D95-Dmin) and the volume of healthy kidney receiving 10-50 Gy (V10-V50) were compared between planned and accumulated distributions. Results: Fifteen patients treated in 75 fractions were included. The depth of the tumor centroid along the beam path varied by up to 17.4 mm relative to the planned anatomy. Depth variations exceeded 5.0 mm in 22.7% of fractions, and resulted in lower iCTV D95, D98, D99, and Dmin ( Conclusion: Skin surface variations may compromise kidney SBPT treatment quality. Further investigation into mitigation strategies, such as adaptive radiotherapy, are merited.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.